Fish Oil and Baby Aspirin Match Antibiotics for Severe Gum Disease
A Brazilian multicenter randomized controlled trial followed 109 adults with severe (stage III/IV) periodontitis for one year after standard deep cleaning. Patients were randomized to placebo, a 14-day course of metronidazole plus amoxicillin, six months of high-dose omega-3 (3 g/day) plus low-dose aspirin (100 mg/day), or both adjuncts together. At one year, 57 to 59 percent of patients in each of the three active arms reached the accepted clinical cure threshold, compared with 23 percent on deep cleaning alone. The host-modulating supplement regimen performed on par with the antibiotic protocol that has the strongest evidence base in periodontics. Combining the two produced no additional benefit, which the authors interpret as a ceiling effect rather than antagonism.
Periodontitis is not a niche dental problem. It affects a large fraction of adults over 45, and the version that matters for longevity is the severe form, where chronic bacterial colonization of the tissue around the tooth root produces a continuous, low-grade inflammatory drip that has been repeatedly associated with cardiovascular disease, cognitive decline, and frailty. Losing teeth is downstream of it, and losing teeth has its own consequences for diet quality and independence in later life.
The standard of care is mechanical: a clinician physically removes the biofilm and calculus from below the gumline. It works, but incompletely. Roughly a third of patients never reach the clinical target, and the usual escalation is systemic antibiotics, specifically the metronidazole plus amoxicillin combination. That escalation carries the familiar costs: side effects, disruption of the microbiome, and a contribution to antimicrobial resistance for what is, in the end, an elective dental outcome.
The big idea in this trial is that you can attack the same problem from the host side rather than the microbial side. Omega-3 fatty acids are the substrate for specialized pro-resolving mediators, the signalling molecules that actively switch off inflammation rather than merely suppressing it. Low-dose aspirin, at these doses, modifies the enzyme COX-2 so that it produces one of these pro-resolving molecules instead of a pro-inflammatory one. The hypothesis is that if you help the tissue resolve inflammation and heal, you get the same clinical result as killing the bacteria, without touching the microbiome.
The trial tested that head to head for the first time, with a placebo arm, blinding, and a full year of follow-up. It worked. The supplement arm hit the clinical endpoint in 57.7 percent of patients versus 58.6 percent for antibiotics, both roughly 2.5 times the 23.1 percent seen with deep cleaning alone. The number needed to treat is about three in either arm, which is a strong number by the standards of most preventive interventions.
The more interesting negative result is that the combination arm did no better than either alone, at 57.1 percent. If the two therapies acted on genuinely independent mechanisms, stacking should have helped. It did not, which suggests both routes converge on the same ceiling: once the infection-inflammation loop is broken, breaking it again adds nothing.
Two caveats sit on top of all of this. The trial recruited only 109 of the 200 patients it planned to, leaving it underpowered at roughly 75 percent. And it deliberately excluded smokers and diabetics, the two groups in whom severe periodontitis is most common.
Actionable Insights
If you have been diagnosed with moderate to severe gum disease and are scheduled for deep cleaning, this trial gives you a supplement protocol worth discussing with your dentist or physician: 3 grams per day of omega-3 fish oil plus 100 mg per day of aspirin, started the day of treatment and continued for six months.
The magnitude is not subtle. Of patients who got only the cleaning, 23 out of 100 reached the clinical target one year later. Of those who added the supplements, 58 out of 100 did. That is 35 additional successes per 100 people treated, or a number needed to treat of about 3. Treat three people, and one extra person reaches a good outcome who otherwise would not have. Statistically, this shows up as a relative risk of 2.50 and an odds ratio of 4.55 versus placebo. In terms of the actual pockets in your mouth, the supplement group converted about 10 more sites from diseased to healthy depth per patient than placebo, and closed 73 percent of deep pockets against 62 percent on cleaning alone. Standardized effect sizes were medium for gaining healthy sites (Cohen’s d around 0.63) and large for reducing deep pockets (Glass’s delta 0.99), meaning a randomly picked supplement patient did better than roughly 67 to 76 percent of placebo patients.
Three practical constraints. This is an add-on, not a replacement, for the mechanical cleaning. Daily aspirin carries real bleeding risk that has to be weighed individually. And every participant here was a non-smoker without diabetes or other systemic disease. [Confidence: Medium for translation to your situation]
Context and Source
- Open Access Paper: Immunomodulators, associated or not with systemic antibiotics, to treat periodontitis: A 1-year multicenter, placebo-controlled, double-blind, randomized clinical trial
- Institutions: Faculdade Israelita de Ciencias da Saude Albert Einstein / Hospital Israelita Albert Einstein, Sao Paulo; Guarulhos University; University of Taubate; University of Sao Paulo (Bauru and Ribeirao Preto schools of dentistry); Sao Paulo State University (Unesp); Universidad Nacional de Colombia and Pontificia Universidad Javeriana, Bogota; Harvard School of Dental Medicine, Boston.
- Country: Brazil (primary), with Colombian and US collaborators.
- Journal: Journal of Periodontology (Wiley, on behalf of the American Academy of Periodontology).
- Impact evaluation: The impact score of this journal is 4.5 (2024 Journal Impact Factor, reported 2025), evaluated against a typical high-end range of 0 to 60+ for top general science, therefore this is a Medium impact journal.